Understanding Systemic Lupus Erythematosus: Causes, Symptoms, and Diagnosis

Lupus nephritis affects many SLE patients, commonly at onset, with increased morbidity and mortality. Clinical suspicion arises in young women with SLE features, hypertension, edema, and proteinuria. Urinalysis shows dysmorphic RBCs, active sediment, and cellular casts. Class 4 (diffuse proliferative) is most common with worst prognosis, presenting with nephritic syndrome and associated with anti-dsDNA positivity and low complement. Class 5 (membranous) presents with nephrotic syndrome. Neuropsychiatric SLE includes psychosis, seizures, and delirium. Laboratory findings in active disease include elevated ESR, anemia (chronic disease or autoimmune hemolytic), and elevated complement consumption.

Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease where the immune system attacks its own tissues, causing widespread inflammation and multi-organ damage. The term derives from Latin for 'wolf,' referencing the characteristic butterfly rash. SLE predominantly affects females 10-fold more than males. Etiology involves genetic factors (HLA-DR2/HLA-DR3, complement deficiencies) interacting with environmental triggers (UV light, smoking, EBV, silica, hormonal factors). Pathophysiology involves type 3 hypersensitivity: cell damage exposes nuclear material, triggering autoantibody production against DNA and histones, forming immune complexes that activate complement and damage organs. Clinical manifestations include constitutional symptoms (fever, fatigue, joint pain in >90%), cutaneous features (malar rash sparing nasolabial folds, discoid rash, periungual telangiectasias), Raynaud's phenomenon, and oral ulcers. Organ involvement includes hematologic cytopenias, renal damage (major mortality cause), cardiac manifestations (pericarditis, myocarditis, Libman-Sacks endocarditis), pulmonary involvement (interstitial lung disease, pulmonary hypertension, antiphospholipid syndrome), and neurologic manifestations (seizures, psychosis, lupus cerebritis). Associated autoimmune conditions frequently coexist, including antiphospholipid syndrome, rheumatoid arthritis, and Sjögren's syndrome. Diagnosis begins with ANA testing (98% sensitivity, titers ≥1:80), followed by specific antibody tests (anti-dsDNA, anti-Smith). The 2019 EULAR/ACR classification requires total score ≥10 with ANA ≥1:80 and at least one clinical domain positive. Treatment follows severity-based approach: hydroxychloroquine as cornerstone therapy; mild disease receives hydroxychloroquine alone; moderate disease receives hydroxychloroquine plus oral glucocorticoids; severe disease requires induction therapy with high-dose IV methylprednisolone followed by maintenance therapy combining hydroxychloroquine, oral steroids, and immunosuppressants (mycophenolate, cyclophosphamide). Biologic therapies are reserved for refractory cases. General management includes sun protection, smoking cessation, and UV avoidance. Hospital admission is indicated for unexplained fever, severe renal involvement, alveolar hemorrhage, neuropsychiatric manifestations, or thrombosis. Monitoring includes latent TB screening before immunosuppressive therapy and annual eye screening for retinal toxicity in patients on long-term hydroxychloroquine.

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease where genetic susceptibility combined with environmental triggers (like UV light, infections, and certain drugs) leads to impaired clearance of apoptotic cells, causing immune sensitization and production of autoantibodies against nuclear and cellular components; this results in widespread inflammation through immune complex deposition and cytokine release, manifesting across multiple organ systems including skin, joints, kidneys, heart, lungs, and brain, with management involving immunosuppressive therapies targeting B and T cells, anti-inflammatory agents, and supportive care for complications like osteoporosis and hypertension.

Neuropsychiatric systemic lupus erythematosus (NPSLE), also known as CNS lupus, affects approximately 50% of lupus patients over their lifetime, presenting with diverse neurological manifestations ranging from seizures and cognitive dysfunction to transverse myelitis and stroke; diagnosis relies on spinal fluid analysis including Q-albumin index (normal <9, elevated 9-15 suggests blood-brain barrier disruption, >15 indicates major breakdown) and IgG index (>0.7 suggests intrathecal immunoglobulin production), while treatment typically involves high-dose steroids with cyclophosphamide for severe cases, and anticoagulation if antiphospholipid antibodies are detected.

Lupus nephritis results from loss of immune tolerance, producing autoantibodies targeting nuclear components. The two-hit model involves predisposition (loss of tolerance) and triggers (hormonal changes, infections). Both innate and adaptive immune systems are involved, with genetic factors contributing to susceptibility.

SLE predominantly affects females (90%), with genetic predisposition on chromosome 6 and 10-year survival of 70-90%. Classic symptoms include fever, rash, joint pain, and anemia, with 50% developing renal involvement. During pregnancy, one-third experience worsening, one-third remain stable, and one-third improve; new-onset SLE indicates severity. Good outcomes require six months of pre-conception disease control and absence of antiphospholipid antibodies, superimposed preeclampsia, or nephritis. Medical management includes low-dose aspirin for mild cases, NSAIDs with caution, prednisolone for severe cases (noting gestational diabetes risk), and azathioprine for refractory cases. Hydroxychloroquine continues safely. Fetal complications include IUGR, oligohydramnios, and neonatal lupus. Continue pregnancy to term unless preeclampsia, IUGR, or preterm labor develop. Neonatal lupus presents with skin lesions (most common), systemic involvement, and hematological abnormalities. Congenital heart block specifically associates with anti-Ro/La antibodies, with risk rising from 2-3% to 25% with prior affected children. Fetal cardiac monitoring between 18-26 weeks is essential when these antibodies are present.

SLE incidence is 28-150 per 100,000, predominantly affecting women. Pregnancy incidence is 1 in 3,300 deliveries. SLE affects pregnancy outcomes: increased mortality (15-20%), higher cesarean rates, hypertension, preeclampsia, and spontaneous abortion. Conversely, pregnancy affects SLE: 1/3 improve, 1/3 stable, 1/3 worsen. Neonatal lupus occurs when mothers have anti-Ro/SSA and anti-La/SSB antibodies, causing congenital heart block in 2% of cases (1 in 20,000), with 20-30% mortality within 3 years. SLE pregnancy monitoring requires distinguishing flare from normal changes: active rash, joint swelling, fever, platelet abnormalities, elevated uric acid, and elevated ESR suggest flare. Steroids are the treatment of choice for flares, being safe especially in the first trimester. Hydroxychloroquine is recommended for all pregnant SLE patients and reduces congenital heart block risk.

SLE significantly increases pregnancy risks: miscarriage (6-35%), stillbirth (0-22%), fetal growth restriction (35%), sudden intrauterine death, preterm delivery (PROM risk ~20%), fetal hydrops, severe anemia (MCA peak systolic velocity), and congenital heart block (2-3% in anti-Ro/La positive mothers, recurrence 16%). Neonatal lupus rash appears as annular lesions on face/scalp. Maternal complications include pulmonary hypertension (mortality 33-40%) and two-to-fourfold higher overall complication rates. Pre-pregnancy evaluation requires echocardiography for cardiac involvement, chest imaging/lung function tests for pulmonary fibrosis, urine analysis/protein-creatinine ratio for renal assessment, and comprehensive blood counts with autoantibody panels (anti-dsDNA, lupus anticoagulant, anticardiolipin) and complement levels (C3, C4).

Neonatal lupus rash appears as annular inflammatory lesions on face and scalp, developing after UV exposure and resolving spontaneously within 3-6 months. Congenital heart block affects 2-3% of fetuses with anti-Ro/anti-La antibodies, with 16% recurrence rate; half require pacing by age one. Glucocorticoids (prednisolone, methylprednisolone, hydrocortisone) are first-line treatments, more efficiently metabolized by placental enzymes than dexamethasone/betamethasone, requiring gestational diabetes screening. Azathioprine and hydroxychloroquine do not require discontinuation during pregnancy. Drug-induced lupus from hydralazine, procainamide, quinidine, isoniazid, minocycline, and diltiazem forms antinuclear antibodies to histone H1/H3 complexes but doesn't flare established lupus. Postpartum care is critical due to increased flare risk; estrogen-containing contraceptives should be avoided. Thrombosis prophylaxis is indicated for antiphospholipid syndrome or previous thrombosis/nephrotic syndrome.

Neonatal lupus occurs in babies born to mothers with systemic lupus, particularly anti-Ro antibody positive mothers. Presentations include malar/rash and complete heart block requiring pacemaker implantation. Treatment involves symptomatic control with hydroxychloroquine or topical steroids for 6-8 months until resolution. Drug-induced lupus is a lupus-like syndrome caused by medications (hydralazine, isoniazid, procainamide, quinidine, phenytoin), presenting with fever, arthritis, fatigue, but lacking skin and renal manifestations. The most accurate diagnostic test is anti-histone antibody. Treatment involves discontinuing the offending drug.

This section covers three major autoimmune rheumatic diseases. SLE presents with joint pain, photosensitivity, and systemic involvement; ANA is most sensitive, anti-dsDNA most specific, with hydroxychloroquine as first-line maintenance. Sjögren's syndrome causes dry eyes/mouth, dental cavities, and corneal ulcers; anti-SSA/SSB antibodies are diagnostic, with risk of MALT lymphoma and neonatal lupus. Rheumatoid arthritis involves MCP/PIP joints with morning stiffness; methotrexate is first-line DMARD, anti-CCP is most specific marker, and TNF inhibitors require TB screening. All three conditions share features of chronic inflammation, joint involvement, and systemic complications.

Autoimmune diseases are classified into organ-specific (affecting single organs like pancreas in type 1 diabetes, thyroid in Hashimoto's) and non-organ-specific (systemic connective tissue diseases). Systemic connective tissue diseases include SLE, Sjögren's syndrome, systemic sclerosis, polymyositis/dermatomyositis, and rheumatoid arthritis. SLE predominantly affects women of childbearing age (20-30 years) with alternating activity and remission periods. Clinical manifestations include cutaneous involvement (malar rash, discoid lupus), joint involvement, and renal involvement. Anti-dsDNA and anti-Sm are specific SLE auto-antibodies; anti-dsDNA has prognostic value for renal involvement. Sjögren's syndrome is characterized by lymphocytic infiltration of exocrine glands causing sicca syndrome (dry eyes, dry mouth), with anti-Ro/SSA and anti-La/SSB as characteristic antibodies. Systemic sclerosis involves three cellular abnormalities: fibroblasts (causing fibrosis), endothelial cells (causing vasculopathy), and immune cells (causing inflammation). Clinical manifestations include Raynaud's phenomenon, skin fibrosis, gastrointestinal involvement, interstitial lung disease, renal crisis, and pulmonary hypertension. Classification is based on skin extent: limited (distal to elbows/knees) and diffuse (proximal to elbows/knees). Anti-centromere antibodies are specific for limited form, while anti-Scl-70 are specific for diffuse form. Polymyositis causes proximal muscle weakness, while dermatomyositis adds characteristic skin involvement (heliotrope rash, Gottron's papules). Anti-Jo-1 is specific for polymyositis/dermatomyositis. Rheumatoid arthritis is characterized by synovial inflammation leading to cartilage and bone destruction, with symmetric small joint involvement and morning stiffness. Anti-CCP is highly specific and appears early in disease progression.

This comprehensive section covers three major autoimmune connective tissue diseases. Sjögren's syndrome presents with dry eyes, dry mouth, and fatigue (Sicca), with extra-glandular manifestations in 30-40% of patients including interstitial nephritis and a 20-fold increased risk of non-Hodgkin's lymphoma. Diagnosis follows a sequence: Schirmer's test, anti-Ro/anti-La antibodies, and salivary gland biopsy. Dermatomyositis presents with proximal muscle weakness, heliotrope rash sparing nasolabial folds, shawl sign, Gottron's papules, and mechanic hands. The first test is CK elevation, followed by myositis panel and EMG. Mixed Connective Tissue Disease (MCTD) presents with overlapping features of SLE, dermatomyositis, and Sjögren's syndrome, characterized by anti-U1 RNP antibodies and at least three of five clinical features.

Mixed Connective Tissue Disease (MCTD) is a systemic autoimmune disorder characterized by overlapping features of SLE, systemic sclerosis, and polymyositis, defined by anti-U1 RNP antibodies. Key features include Raynaud's phenomenon, puffy fingers, and myositis. Many connective tissue diseases share common clinical features: arthralgia/arthritis, Raynaud's phenomenon, photosensitivity, myalgia and weakness, dry eyes and mouth, skin changes, and constitutional symptoms (fatigue, weight loss, low-grade fever). Different diseases have characteristic manifestations: SLE (malar rash, oral ulcers, renal involvement), RA (symmetric small joint arthritis, morning stiffness), Systemic sclerosis (skin thickening, Raynaud's), Sjögren's (dry eyes and mouth), and Polymyositis/Dermatomyositis (proximal muscle weakness, characteristic rashes). Recognizing these patterns aids diagnosis.

Mixed Connective Tissue Disease (MCTD) is a systemic autoimmune disorder characterized by clinical features overlapping with lupus, systemic sclerosis, polymyositis, dermatomyositis, and rheumatoid arthritis, but distinguished immunologically by the presence of anti-U1 RNP antibodies (specifically against the 70-kDa subprotein) as the sole positive marker, with diagnosis requiring at least three clinical criteria including Raynaud phenomenon, arthritis, myositis, and sclerodactyly, and treatment tailored to specific manifestations such as calcium channel blockers for Raynaud phenomenon, NSAIDs and hydroxychloroquine for arthritis, and corticosteroids for myositis and pericarditis.